Linked Life Data

16227742

Source:http://linkedlifedata.com/resource/pubmed/id/16227742

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2005-10-17
pubmed:abstractText
The present study investigated the efficacy and feasibility of weekly paclitaxel for advanced/recurrent gastric cancer. Subjects comprised 23 patients with advanced/recurrent gastric cancer who had been treated using a 5-FU-containing regimen. Paclitaxel was administered at a dose of 80 mg/m(2), 3 times every 4 weeks. Dexamethasone, diphenhydramine and ranitidine chloride were given 30 min before paclitaxel as premedication. The mean number of treatment cycles was 6.4 (range, 1-28). Response rate was 40.0% (4/10) with measurable lesions. Among 13 patients without measurable lesions, 3 cases revealed improvements on colonography, 1 case displayed decreased ascites on abdominal computed tomography, and 1 case recovered from disseminated intravascular coagulopathy due to bone metastases. Median survival time was 258 days, and median time to progression was 140 days. Grade 3 leukocytopenia and neutropenia occurred in 13.0% of patients. All non-hematological toxicity was low-grade, including that involving the gastrointestinal system. Weekly paclitaxel appears effective and safe for 5-FU-refractory gastric cancer.
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0385-0684
pubmed:author
pubmed:issnType
Print
pubmed:volume
32
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1427-30
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
[Feasibility study of weekly paclitaxel as second-line chemotherapy against 5-FU-refractory gastric carcinoma].
pubmed:affiliation
Dept.of Gastroenterological Surgery, Aichi Cancer Center Hospital.
pubmed:publicationType
Journal Article, English Abstract